| 2025-11-10 |
详情>>
股本变动：
变动后总股本15913.17万股
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.04美元,归母净利润-3452.7万美元,同比去年增长4.64%
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益-0.03美元,归母净利润-2750.3万美元,同比去年增长-29.68%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.02美元,归母净利润-1288.7万美元,同比去年增长-43.97%
|
| 2025-04-08 |
股东大会：
将于2025-05-13召开股东大会
会议内容 ▼▲
- 1.That the annual report and accounts for the year ended December 31, 2024, together with the directors’ report and independent auditor’s report thereon, be received and adopted.
2.That PricewaterhouseCoopers LLP (“PwC”) be re-appointed as auditors to hold office from the conclusion of the annual general meeting until the conclusion of the next annual general meeting at which the Company’s annual report and accounts are presented.
3.That the Audit and Risk Committee be authorized to determine PwC’s remuneration.
4.That the directors’ remuneration report (excluding the directors’ remuneration policy), as set out in the Company’s annual report and accounts for the year ended December 31, 2024, be approved.
5.That the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis.
6.That the frequency of future advisory votes on the compensation of the Company’s named executive officers be approved, on an advisory (non-binding) basis.
7.That Dr. Deepika Pakianathan be re-appointed as a director of the Company.
8.That Dr. Pierre Jacquet be re-appointed as a director of the Company.
9.That Michael Wyzga be re-appointed as a director of the Company.
|
| 2025-03-26 |
详情>>
业绩披露：
2024年年报每股收益-0.06美元,归母净利润-4325.3万美元,同比去年增长-46.79%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.05美元,归母净利润-3620.7万美元,同比去年增长-77.86%
|
| 2024-09-12 |
详情>>
内部人交易：
Fox Christine Ann等共交易12笔
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-0.03美元,归母净利润-2120.8万美元,同比去年增长-92.28%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.01美元,归母净利润-895.1万美元,同比去年增长25.88%
|
| 2024-04-24 |
股东大会：
将于2024-05-23召开股东大会
会议内容 ▼▲
- 1.That the annual report and accounts for the year ended December 31, 2023, together with the directors’ report and independent auditor’s report thereon, be received and adopted.
2.That PricewaterhouseCoopers LLP (“PwC”) be re-appointed as auditors to hold office from the conclusion of the annual general meeting until the conclusion of the next annual general meeting at which the Company’s annual report and accounts are presented.
3.That the Audit and Risk Committee be authorized to determine PwC’s remuneration.
4.That the directors’ remuneration report (excluding the directors’ remuneration policy), as set out in the Company’s annual report and accounts for the year ended December 31, 2023, be approved.
5.That Dr. Denise Scots-Knight be re-appointed as a director of the Company.
6.That Dr. Jeremy Bender be re-appointed as a director of the Company.
7.That Dr. Anders Ekblom be re-appointed as a director of the Company.
|
| 2024-03-27 |
详情>>
业绩披露：
2023年年报每股收益-0.04美元,归母净利润-2946.6万美元,同比去年增长30.21%
|
| 2024-03-27 |
详情>>
业绩披露：
2022年年报每股收益-0.07美元,归母净利润-4222万美元,同比去年增长-431.79%
|
| 2023-09-07 |
详情>>
业绩披露：
2023年中报每股收益-0.02美元,归母净利润-1103万美元,同比去年增长42.43%
|
| 2023-03-28 |
详情>>
业绩披露：
2021年年报每股收益0.02美元,归母净利润1272.50万美元,同比去年增长107.78%
|
| 2022-10-21 |
股东大会：
将于2022-11-18召开股东大会
会议内容 ▼▲
- 1.Mereo is working in the best interests of all shareholders to execute on its strategic plan, which is the most compelling and financially responsible way to unlock the opportunities for potential life-changing therapies in our pipeline while maintaining the resources required to deliver maximum shareholder value from these assets, in line with program updates and the broader operating environment.
2.Rubric’s plan appears to depend on near-term licensing or selling of Mereo’s key assets, which is irresponsible and sub-optimal, and then a cash distribution, which fails to account for the complexities under English law with respect to distributions.
3.Rubric’s nominees are woefully underqualified, particularly when compared to the directors they would replace.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-16 |
股东大会：
将于2021-05-27召开股东大会
会议内容 ▼▲
- 1.That the Company’s annual report and accounts for the financial year ended December 31, 2020, together with the directors’ report and independent auditor’s report thereon, be received and adopted.
2.That Ernst & Young LLP be re-appointed as auditors to hold office from the conclusion of the AGM until the conclusion of the next Annual General Meeting at which the Company’s annual report and accounts are presented.
3.That the directors of the Company be authorized to determine Ernst & Young LLP’s remuneration.
4.That the directors’ remuneration report (excluding the directors’ remuneration policy, set out on pages 39 to 61 of the directors’ remuneration report), as set out in the Company’s annual report and accounts for the financial year ended December 31, 2020, be approved.
5.That the directors’ remuneration policy, as set out on pages 42 to 51 of the directors’ remuneration report, which takes effect immediately after the end of AGM, be approved.
6.That Dr. Jeremy Bender be re-appointed as a director of the Company.
7.That Dr. Brian Schwartz be re-appointed as a director of the Company.
8.That Dr. Peter Fellner be re-appointed as a director of the Company.
9.That Dr. Denise Scots-Knight be re-appointed as a director of the Company.
10.That Peter Bains be re-appointed as a director of the Company.
11.That Dr. Anders Ekblom be re-appointed as a director of the Company.
12.That Kunal Kashyap be re-appointed as a director of the Company.
|
| 2021-01-14 |
股东大会：
将于2021-02-01召开股东大会
会议内容 ▼▲
- 1.That, in addition to any authority previously conferred upon the Directors pursuant to section 551 of the Companies Act 2006 (the “Act”), the Directors be generally and unconditionally authorised in accordance with section 551 of the Act to exercise all the powers of the Company to allot shares in the Company or to grant rights to subscribe for, or to convert any securities into, shares in the Company up to a maximum aggregate nominal amount of ￡1,540,760.28, such authority to expire on 30 June 2023, save that the Company may, before such expiry, make offers or agreements which would, or might, require shares to be allotted or rights to subscribe for or to convert any securities into shares to be granted after such expiry and the Directors may allot shares or grant such rights under any such offer or agreement as if the authority conferred by this resolution had not expired.
2.That, subject to the passing of resolution 1 and in addition to any power previously conferred upon the Directors pursuant to Chapter 3 of Part 17 of the Act, the Directors be generally empowered pursuant to section 570 and section 573 of the Act to allot equity securities for cash pursuant to the authority given by resolution 1 and to sell equity securities held as treasury shares for cash pursuant to section 727 of the Act, in each case as if section 561(1) of the Act did not apply to any such allotment or sale, provided that this power shall be limited to the allotment or sale of equity securities up to an aggregate nominal value of ￡1,540,760.28, such power to expire on 30 June 2023, save that the Company may, before such expiry, make offers or agreements which would or might require equity securities to be allotted and equity securities held as treasury shares to be sold after such expiry, and the Directors may allot equity securities and sell equity securities held as treasury shares in pursuance of any such offer or agreement as if the power conferred hereby had not expired.
|
| 2020-09-29 |
财报披露：
美东时间 2020-09-29 盘前发布财报
|
| 2020-09-04 |
股东大会：
将于2020-09-28召开股东大会
|
| 2020-05-22 |
股东大会：
将于2020-06-29召开股东大会
|
| 2020-03-19 |
复牌提示：
2020-03-19 09:58:53 停牌，复牌日期 2020-03-19 10:03:53
|